Literature DB >> 12773271

Outcome of schizophreniform disorder.

Franco Benazzi1.   

Abstract

The aim of this review is to find data about the outcome of schizophreniform disorder. As different definitions of schizophreniform disorder were found in the literature, it was not surprising that data on its outcome, and on the relationship of schizophreniform disorder to schizophrenia and to mood disorders (as this relationship is linked to outcome), were often different and opposite. Its classic description of an acute onset psychotic episode with mood instability and a relatively brief duration should be the focus of future studies. Current studies, apart from a small number, lump together different (and probably distinct) subtypes of schizophreniform disorder (one with good prognostic features, and one without good prognostic features, according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition). Studies of mixed samples led to different results, probably depending on the relative prevalence of one subtype over the other one. The few studies on schizophreniform disorder with good prognostic features found more often an episodic, recurrent course, and a family history of mood disorders. These features link this schizophreniform disorder subtype more to mood disorders than to schizophrenia. If confirmed by future studies, these preliminary findings can have very important treatment implications, given the very different treatment strategies in mood disorders compared with schizophrenia.

Entities:  

Mesh:

Year:  2003        PMID: 12773271     DOI: 10.1007/s11920-003-0041-1

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  38 in total

1.  Left ventricular enlargement associated with diagnostic outcome of schizophreniform disorder.

Authors:  L E DeLisi; A L Hoff; M Kushner; A Calev; P Stritzke
Journal:  Biol Psychiatry       Date:  1992-07-15       Impact factor: 13.382

2.  Refining the diagnosis of schizophreniform disorder.

Authors:  M Beiser; J A Fleming; W G Iacono; T Y Lin
Journal:  Am J Psychiatry       Date:  1988-06       Impact factor: 18.112

3.  DSM-III-R schizophreniform disorder with good prognostic features: a six-year follow-up.

Authors:  F Benazzi
Journal:  Can J Psychiatry       Date:  1998-03       Impact factor: 4.356

4.  Clinical subtypes of bipolar mixed states: validating a broader European definition in 143 cases.

Authors:  G Perugi; H S Akiskal; C Micheli; L Musetti; A Paiano; C Quilici; L Rossi; G B Cassano
Journal:  J Affect Disord       Date:  1997-05       Impact factor: 4.839

5.  Psychiatric morbidity in the relatives of patients with DSM-III schizophreniform disorder: comparisons with the relatives of schizophrenic and bipolar disorder patients.

Authors:  A E Pulver; C H Brown; P S Wolyniec; J A McGrath; D Tam
Journal:  J Psychiatr Res       Date:  1991       Impact factor: 4.791

6.  A follow-up study of patients with DSM-IV schizophreniform disorder.

Authors:  Iulian Iancu; Pinhas N Dannon; Reuven Ziv; Elie Lepkifker
Journal:  Can J Psychiatry       Date:  2002-02       Impact factor: 4.356

7.  Paranoid (delusional) disorders in the light of a long-term follow-up study.

Authors:  S Opjordsmoen
Journal:  Psychopathology       Date:  1991       Impact factor: 1.944

8.  The Roscommon Family Study. I. Methods, diagnosis of probands, and risk of schizophrenia in relatives.

Authors:  K S Kendler; M McGuire; A M Gruenberg; A O'Hare; M Spellman; D Walsh
Journal:  Arch Gen Psychiatry       Date:  1993-07

9.  Outcome after 40 years in DSM-III schizophreniform disorder.

Authors:  W Coryell; M T Tsuang
Journal:  Arch Gen Psychiatry       Date:  1986-04

10.  Schizophreniform disorder, delusional disorder and psychotic disorder not otherwise specified: clinical features, outcome and familial psychopathology.

Authors:  K S Kendler; D Walsh
Journal:  Acta Psychiatr Scand       Date:  1995-06       Impact factor: 6.392

View more
  1 in total

Review 1.  Clozapine dose for schizophrenia.

Authors:  Selvizhi Subramanian; Birgit A Völlm; Nick Huband
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.